Fisetin in Mild Alzheimer's Disease
Recruiting
Phase 2
Interventional Study
Alzheimer s Disease
Alzheimer Dementia
Alzheimer Dementia (AD)
Alzheimer Disease
Mild Cognitive Disorder
Neurocognitive Disorders, Mild
Neurocognitive Disorder
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 60 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 5 (estimated)
- Sponsor
- Sunnybrook Health Sciences Centre · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia
* Moca score of 11 or higher
* Stable psychotropics and cognitive enhancing medications
Exclusion Criteria:
* Known hypersensitivity or allergy to fisetin
* Presence of any medical condition, or …
Contacts